肝移植术后血管胆道并发症的介入治疗

目的:评价介入治疗对肝移植后胆道、血管并发症的价值。材料和方法:18例肝移植患者接受了介入治疗。其中肝动脉狭窄8例,行肝动脉造影及溶栓治疗;下腔静脉及肝静脉狭窄2例,行内支架置入术;胆瘘及胆道狭窄8例,行PTCD治疗。结果:胆道并发症8例,PTCD治疗后症状消失;肝动脉狭窄8例,溶栓后肝动脉完全开放6例,1例血流部分开放,1例肝动脉血流未恢复再次肝移植治疗;下腔静脉及肝静脉狭窄2例内支架置入术后下腔静脉梗阻及肝肿大症状消失。结论:介入治疗是治疗肝移植后胆道血管并发症的有效方法。     

经皮穿脾食管胃底静脉曲张栓塞术治疗食管胃底静脉曲张

自 1974年瑞典人Ｌｕｎｄｅｒｑｕｉｓｔ和Ｖａｎｇ首先介绍了经皮穿肝胃食管曲张静脉栓塞术 ( ｐｅｒｃｕｔａｎｅｏｕｓｔｒａｎｓｈｅｐａｔｉｃｖａｒｉｃｅａｌｅｍｂｏｌｉｚａｔｉｏｎ ,ＰＴＶＥ)后 ,许多学者对其进行了广泛研究 ,证实ＰＴＶＥ在控制急性出血、降低病死率等方面有明显疗效。但其存在着门静脉主干必须保持通畅的缺陷[1] ,因此对于原发性肝癌合并门静脉癌栓闭塞病人 ,建立另一门静脉插管通道栓塞曲张静脉显得格外重要。 1999年 8月至 2 0 0 0年 1月 ,我们对 12例上述病人采用经皮穿脾胃底食管曲张静脉栓塞术 ( ｐｅｒ…     

门静脉支架联合动脉化学栓塞疗法治疗肝癌合并门静脉主干癌栓

肝癌(HCC)伴有门静脉主干癌栓(MPVTT)预后极差.由被阻塞门静脉供血的正常肝组织缺血,从而损害肝功能并限制了经肝动脉化疗栓塞(TACE)在治疗HCC中的应用.经皮穿刺肝脏门静脉支架植入(PTPVS)可姑息性解除门静脉阻塞.     

中西医结合治疗急性盆腔脓肿30例临床分析

目的探讨中西医结合治疗急性盆腔脓肿的有效性。方法对2004~2005年收治的30例急性盆腔脓肿的病例的临床资料进行回顾性分析。结果治愈33.3%,显效53.3%,有效13.3%,无效0%。结论中西医结治疗急性盆腔脓肿是行之有效的,能取得较彻底的疗效。     

输卵管炎性不孕的盆腔状况与中医证候的关系分析

目的探讨输卵管炎性患者的盆腔状况与中医辨证分型的关系,为中医证候分型提供客观依据,使其更客观、更科学。并为中西医结合治疗输卵管炎性不孕症提供理论依据。方法对在我院妇科住院,经腹腔镜检确诊为输卵管炎性不孕的患者的盆腔状况与其中医证型进行对比分析。结果①纳入研究的46例患者中,气滞血瘀型所占比例最大。②4个不同中医证候比较,4组均存在盆腔粘连,组间盆腔粘连程度无显著性差异。③4个不同中医证候比较,4组间充血程度有差异,其中湿热瘀结组与其他3组有显著性差异。④4个不同中医证候比较,4组间渗液程度有差异,其中湿瘀互结组与其他3组有显著性差异。⑤纳入研究的患者的腹腔液UU感染与宫颈分泌物UU感染有显著性差异。结论输卵管炎性不孕的患者的致病因素主要为“瘀”,瘀是致病因素,亦是病理产物。不同证型之间因其有不同的夹杂证,盆腔状况亦有不同的侧重,这些不同的侧重与夹杂证的病理本质相关。对输卵管炎性不孕患者的腹腔液进行UU培养,阳性率较低,与取患者的宫颈分泌物作UU培养相比,腹腔液的病原体检测并不能更有效的说明盆腔炎患者的病原体感染情况。     

彩色高频超声多普勒对指（趾）远端血管球瘤的诊断价值

目的探讨彩色高频超声多普勒对指（趾）远端血管球瘤的早期诊断价值。方法对9例可疑病例进行术前彩色高频超声检查、X线检查及术中探查、术后病理检查,将上述结果分析,研究彩色高频超声在指（趾）远端血管球瘤早期诊断作用及声像学特点。结果9例患者的彩色高频超声检查结果、术中探查结果、病理检查结果符合率100％,彩色高频超声检查表现为肿块内丰富的血流信号,呈特征性“彩球状”,并可探及动静脉瘘血流频谱及低速低阻血流。结论高频彩色超声是一种简便、有效的早期诊断指（趾）端血管球瘤的方法。     

梨状肌综合征治疗研究

治疗梨状肌综合征的方法较多,如针灸、推拿、药物、针刀、物理疗法、中西医结合疗法、民族医药疗法等,每种方法各有优点,并有一定的治疗效果.临床采取综合疗法治疗梨状肌综合征能互补不足,提高临床疗效.     

动脉化疗栓塞治疗恶性梗阻性黄疸

目的：探讨胆道支架置放后动脉化疗栓塞治疗恶性梗阻性黄疸(MOJ)的并发症和疗效，研究影响黄疸复发时间和患者生存期的预后因素。方法：51例MOJ患者放置胆道支架后接受动脉化疗栓塞术(TACE)，观察手术并发症，血清胆红素下降程度，随访黄疸复发时间和患者生存期。分析性别，年龄，肿瘤类型，术前血清胆红素浓度、碱性磷酸酶、谷丙转氨酶、白蛋白、血红蛋白浓度，梗阻时间，梗阻水平10个因素对黄疸复发时间和患者生存期的影响。结果：51例共计放置支架64枚，行TACE术86次，技术成功率为100％。1例于术后1个月死亡，在治疗过程中，4例出现肝脓肿。4例失访，51例生存期为1～34个月，平均9．0个月，中位值8．0个月。22例黄疸复发，复发率43．2％，黄疸复发时间2～14个月，平均11．0个月，中位值9．0个月。单因素(P=0．010)和多因素(P=0．010)分析均显示术前血清总胆红素浓度是影响患者生存期的重要因素。单因素分析显示对黄疸复发有显著影响的因素为肿瘤类型(P=0．035)。结论：MOJ患者放置胆道支架后进行TACE术，可以延缓黄疸复发，延长患者生存期。术前血清总胆红素浓度高的患者生存期较短；肝细胞肝癌患者的黄疸复发时间较非肝细胞肿瘤患者明显延长，黄疸复发率亦低于后者。     

金属内支架置入联合三维适形放射治疗肝癌合并门静脉癌栓

Objective To study the clinical efficiency of metallic stent implantation in combination with three-dimensional conformal radiation therapy in the treatment of hepatocellular carcinoma (HCC) pa-tients with portal vein tumor thrombus. Methods 22 cases of HCC patients with portal vein tumor thrombus were devided into 2 groups: 10 patients (group A) recieved stent implantation in combination with conformal radiation therapy, 12 patients (group B) recieved stent implantation and transcatheter arterial chemoembolization. The adverse reactions, and liver function before and after treatment were compared between the two groups. The stent patency rate at 4, 6 and 12 months and the survival rate at 3, 6 and 12 months were followed up. Comparison of liver function was analyzed by Wilcoxon signed rank test. Compari-son of stent patency rate curves and survival curves was analyzed by Log rank test. Results The portal vein catheterization was successful in all the patients. The stents were successfully implanted by transhepatic portal vein approach, and portal vein stenosis was re-opened. There was no abdominal hemorrhage in all the patients, but there were symptoms of abdominalgia, fever, nausea, vomiting and flatulence of varying de-grees after interventional operation, and these symptoms were relieved by symptomatic treatment in one week. All patients in group A completed the treatment. Ⅰ-Ⅱ degree gastrointestinal tract reactions occurred in 3 cases, Ⅰ-Ⅱ degree myelosuppression occurred in 2 cases, and they were all completely relieved after treatment. The stent patency rate at 4, 6 and 12 months was 90%, 70%, 30% in group A; and 50%, 25%, 16.7% in group B (P < 0.05). The survival rate at 3, 6 and 1 2 months was 100%, 80%, 30% in group A and 91.7%, 41.7%, 16.7% in group B (P < 0.05). Conclusion Stent implantation combined with three-dimensional conformal radiation therapy is a good treatment for hepatocellular carcinoma with portal vein tumor thrombus and causes less damage to liver.     

金属内支架置入联合三维适形放射治疗肝癌合并门静脉癌栓

Objective To study the clinical efficiency of metallic stent implantation in combination with three-dimensional conformal radiation therapy in the treatment of hepatocellular carcinoma (HCC) pa-tients with portal vein tumor thrombus. Methods 22 cases of HCC patients with portal vein tumor thrombus were devided into 2 groups: 10 patients (group A) recieved stent implantation in combination with conformal radiation therapy, 12 patients (group B) recieved stent implantation and transcatheter arterial chemoembolization. The adverse reactions, and liver function before and after treatment were compared between the two groups. The stent patency rate at 4, 6 and 12 months and the survival rate at 3, 6 and 12 months were followed up. Comparison of liver function was analyzed by Wilcoxon signed rank test. Compari-son of stent patency rate curves and survival curves was analyzed by Log rank test. Results The portal vein catheterization was successful in all the patients. The stents were successfully implanted by transhepatic portal vein approach, and portal vein stenosis was re-opened. There was no abdominal hemorrhage in all the patients, but there were symptoms of abdominalgia, fever, nausea, vomiting and flatulence of varying de-grees after interventional operation, and these symptoms were relieved by symptomatic treatment in one week. All patients in group A completed the treatment. Ⅰ-Ⅱ degree gastrointestinal tract reactions occurred in 3 cases, Ⅰ-Ⅱ degree myelosuppression occurred in 2 cases, and they were all completely relieved after treatment. The stent patency rate at 4, 6 and 12 months was 90%, 70%, 30% in group A; and 50%, 25%, 16.7% in group B (P < 0.05). The survival rate at 3, 6 and 1 2 months was 100%, 80%, 30% in group A and 91.7%, 41.7%, 16.7% in group B (P < 0.05). Conclusion Stent implantation combined with three-dimensional conformal radiation therapy is a good treatment for hepatocellular carcinoma with portal vein tumor thrombus and causes less damage to liver.